Adagrasib

Definition

An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

NCIT:C157493 · NCI Thesaurus OBO Edition · CC BY 4.0

Also known as ADAGRASIB, KRAS G12C Inhibitor MRTX849, Krazati, MRTX 849, MRTX-849, MRTX849 — per NCIT

Also identified as

ATC L01XX77 per RXNORM
NCIT NCIT:C157493 per NCIT
UNII 8EOO6HQF8Y per RXNORM

Indications

Disease	Relation	Source
Non-small cell lung carcinoma	may treat	MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ	Side effect / interaction	Source
Lungs	may treat a disease of this organ	DERIVED · CC BY 4.0

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.